The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ryzhova M.V.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva

Shishkina L.V.

Burdenko Neurosurgery Institute, Moscow, Russia

Comparative assessment of molecular abberation in medulloblastomas

Authors:

Ryzhova M.V., Shishkina L.V.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2012;76(6): 66‑72

Read: 2994 times

Download PDF (RU)
Contact the author
Table of contents

COMPARATIVE ASSESSMENT OF MOLECULAR ABBERATION IN MEDULLOBLASTOMAS
COMPARATIVE ASSESSMENT OF MOLECULAR ABBERATION IN MEDULLOBLASTOMAS

To cite this article:

Ryzhova MV, Shishkina LV. Comparative assessment of molecular abberation in medulloblastomas. Burdenko's Journal of Neurosurgery. 2012;76(6):66‑72. (In Russ.)

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Medulloblastoma is a heterogeneous disease with molecular variants and distinct biological behavior. Studying molecular abnormalities in medulloblastomas will allow to stratify patients into key populations and optimize aduvant therapy reducing long-term adverse effects.

Keywords:

medulloblastoma
amplification MYC
isochromosome 17q
Sonic Hedgehog SHH signal pathway
Wnt/Wingless signal pathway

Authors:

Ryzhova M.V.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva

Shishkina L.V.

Burdenko Neurosurgery Institute, Moscow, Russia

Close metadata

References:

  1. Adesina A.M. Molecular heterogeneity in medulloblastoma with implications for differing tumor biology. J Child Neurol 1999; 14: 411-417.
  2. Aldosari N., Bigner S.H., Burger P.C. et al. MYCC and MYCN oncogene amplification in medulloblastoma. Arch Pathol Lab Med 2002; 126: 540-544.
  3. Aldosari N., Rasheed B.K.A., McLendon R.E. et al. Characterization of chromosome 17 abnormalities in medulloblastomas. Acta Neuropathol 2000; 99: 345-351.
  4. Al-Halabi H., Nantel A., Klekner A. et al. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma. Acta Neuropathol 2010; 121: 2: 229-239 DOI: 10.1007/s00401-010-0780-0.
  5. Altaba A.R., Sanchez P., Dahmane N. Gli and Hedgehog in cancer: tumours, embryos and stem cells. Nature Review. Cancer 2002; 2: 361-372.
  6. Bar E.E., Chaudhry A., Farah M.H., Eberhart C.G. Hedgehog signaling promotes medulloblastoma survival via Bc/II. Am J Pathol 2007; 170: 347-355.
  7. Baryawno N., Sveinbjornsson B., Kogner P., Johnsen J.I. Medulloblastoma a disease with disorganized developmental signaling cascades. Cell Cycle 2010; 9: 13: 2548-2554.
  8. Bayani J., Zielenska M., Marrano P. et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 2000; 93: 437-448.
  9. Beauchamp E.M., Ringer L., Bulut G. et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 2011; 121: 1: 148-160.
  10. Bont J.M. de, Packer R.J., Michiels E.M. et al. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neurol Oncol 2008; 10: 1040-1060.
  11. Boon K., Eberhart C.G., Riggins G.J. Genomic amplification of Orthodenticle Homologue 2 in medulloblastomas. Cancer Res 2005; 65: 3: 703-707.
  12. Boon K., Edwards J., Siu I-M. et al. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 2003; 22: 7687-7694.
  13. Bruggers C.S., Tai K.-F., Murdock T. et al. Expression of the c-Myc protein in childhood medulloblastoma. J Pediat Hematol Oncol 1998; 20: 1: 18-25.
  14. Buhren J., Christoph A.H.A., Buslei R. et al. Expression of the neurotrophin receptor p75NTR in medulloblastomas is correlated with distinct histological and clinical features: evidence for a medulloblastoma subtype derived from the external granule cell layer. J Neuropathol Exp Neurol 2000; 59: 3: 229-240.
  15. Castellino R.C., Bortoli M.De, Lu X. et al. Medulloblastomas overexpess the p53-inacrivating oncogene WIP1/PPM1D. J Neurooncol 2008; 86: 3: 245-256. DOI: 10.1007/s11060-007-9470-8.
  16. Clifford S.C., Lusher M.E., Lindsey J.C. et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006; 5: 22: 2666-2670.
  17. Cong F., Zhang J., Pao W. et al. A protein knockdown strategy to study the function of Β-catenin in tumorigenesis. BMC Mol Biol 2003; 4: 10.
  18. Corcoran A., Maestro R.F.Del. Testing the "Go or Grow" hypothesis in human medulloblastoma cell lines in two and three dimentions. Neurosurgery 2003; 53: 174-183.
  19. Dahmen R.P., Koch A., Denkhaus D. et al. Deletion of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Research 2001; 61:7039-7043.
  20. Di C., Liao S., Adamson D.C. et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans-retinoic acid. Cancer Res 2005; 65: 719-724.
  21. Duman-Scheel M., Weng L., Xin S., Du W. Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature 2002; 417: 299-304.
  22. Eberhart C.G. In search of the medulloblast: neuronal stem cells and embryonal brain tumor. Neurosurg Clin North Am 2007; 18: 59-69.
  23. Eberhart C.G. Molecular diagnosis in embrional brain tumors. Brain Pathol 2011; 21: 96-101.
  24. Eberhart C.G., Kratz J., Wang Y. et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004; 63: 5: 441-449.
  25. Eberhart C.G., Tihan T., Burger P.C. Nuclear localization and mutation of Β-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000; 59: 4: 333-337.
  26. Ellison D.W. Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol 2010; 120: 3: 305-316.
  27. Ellison D.W., Dalton J., Kocak M. et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011; DOI: 10.1007/s00401-011-0800-8.
  28. Ellison D.W., Kocak M., Dalton J. et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2010; 28. DOI: 10.1200/JCO.2010.30.2810.
  29. Ellison D.W., Onilude O.E., Lindsey J.C. et al. Β-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children,s Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005; 23: 7951-7957.
  30. Fan X., Eberhart C.G. Medulloblastoma stem cells. J Clin Oncol 2008; 26: 17: 2821-2827.
  31. Fan X., Matsui W., Khaki L. et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66: 15: 7445-7452.
  32. Fangusaro J.R., Jiang Y., Holloway M.P. et al. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005; 92: 359-365.
  33. Fisher P.G., Burger P.C., Eberhart C.G. Biologic risk stratification of medulloblastoma: the real time is now. J Clin Oncol 2004; 22: 6: 971-974.
  34. Fruhwald M.C., OȼDorisio M.S., Dai Z. et al. Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Gen Chromosom Cancer 2001; 30: 38-47.
  35. Fruhwald M.C., OȼDorisio M.S., Dai Z. et al. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - implications for tumor biology and potential clinical utility. Oncogene 2001; 20: 5033-5042.
  36. Gessi M., Muehlen A.Z., Lauriola L. et al. TP53, Β-catenin and c-myc/ N-myc status in embryonal tumours with ependymoblastic rosettes. Neuropathol Appl Neurobiol 2011; 37: 406-413.
  37. Giangaspero F., Wellek S., Masuoka J. et al. Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol 2006; 112: 5-12.
  38. Gilbertson R.J. Medulloblastoma: signaling a change in treatment. Lancet Oncol 2004; 5: 209-218.
  39. Gilbertson R.J., Gajjar A. Molecular biology of medulloblastoma: will it ever make a difference to clinical management? J Neurol Oncol 2005; 75: 273-278.
  40. Giordana M.T., Migheli A., Pavanelli E. Isochromosome 17q is a constant finding in medulloblastoma. An interphase cytogenetic study on tissue sections. Neuropathol Appl Neurobiol 1998; 24: 233-238.
  41. Grotzer M.A., Hogarty M.D., Janss A.J. et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001; 7: 2425-2433.
  42. Haas T. de, Hasselt N., Troost D. et al. Molecular risk stratification of medulloblastoma patient based on immunohistochemical analysis of MYC, LDYB, and CCNB1 expression. Clin Cancer Res 2008; 14: 13: 4154-4160.
  43. Haas T.G.K.J. de, Kool M. Clinicopathological features of medulloblastoma: an overview with an emphasis on molecular biology. Clin Neuropathol 2007; 26: 3: 93-110.
  44. Hallhan A.R., Pritchard J.I., Hansen S. et al. The SmoA1 mouse model reveals that Notch signaling is critical for the growth and survival of Sonic Hedgehog-induces medulloblastomas. Cancer Res 2004; 64: 7794-7800.
  45. Hambardzumyan D., Becher O.J., Holland E.C. Cancer stem cells and survival pathways. Cell Cycle 2008; 7: 10: 1371-1378.
  46. Herms J., Neidt I., Luscher B. et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer (Pred Oncol) 2000; 89: 395-402.
  47. Holland H., Koschny R., Krupp W. et al. Cytogenetic and molecular biological characterization of an adult medulloblastoma. Cancer Genet Cytogenet 2007; 178: 104-113.
  48. Horbinski C., Miller C.R., Perry A. Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 2011; 21: 57-73.
  49. Howng S.-L., Wu C.-H., Cheng T.-S. et al. Differential expression of Wnt genes, Β-catenin and E-cadherin in human brain tumors. Cancer Lett 2002; 183: 950101.
  50. Huang H., Mahler-Araujo B.M., Sankila A. et al. APC mutation in sporadic medulloblastomas. Am J Pathol 2000; 156: 433-437.
  51. Jung H.L., Wang K-C., Kim S-K. et al. Loss of heterozygosity analysis of chromosome 17p13.1-13.3 and its correlation with clinical outcome in medulloblastomas. J Neurol Oncol 2004; 67: 1-2: 41-46.
  52. Kagawa N., Maruno M., Suzuki T. et al. Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays. Brain Tumor Pathol 2006; 23: 41-47.
  53. Kasuga C., Nakahara Y., Ueda S. et al. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. J Neurosurg Pediat 2008; 1: 305-313.
  54. Katoh M. WNT/PCP signaling pathway and human cancer (review). Oncol Rep 2005; 14: 1583-1588.
  55. Kenney A.M., Cole M.D., Rowitch D.H. Nmyc upregulation by Sonic Hedgehog Signaling promotes proliferation in developing cerebellar granule neuron precusors. Development 2003; 130: 15-28.
  56. Kim S.-K., Kim S.U., Park I.H. et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 2006; 12: 18: 5550-5556.
  57. Kleihues P., Burger P.C., Aldape K.D. et al. WHO classification of tumours of the central nervous system. Eds. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee. Lyon 2007; 132-140.
  58. Koch A., Hrychyk A., Hartmann W. et al. Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer 2007; 121: 284-291.
  59. Kool M., Koster J., Bunt J. et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetics profiles, patway signature and clinicopathological features. Plos one 2008; 3: 8: 1-14.
  60. Korshunov A., Benner A., Remke M. et al. Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathol 2008; 16: 4: 383-390, DOI: 10.1007/s00401-008-0422-y.
  61. Korshunov A., Remke M., Werft W. et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 2010; 28: 18: 3054-3060.
  62. Lamont J.M., Mcmanamy C.S., Pearson A.D. et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004; 10: 5482-5493.
  63. Lee Y., McKinnon P.J. DNA ligase IV suppresses medulloblastoma formation. Cancer Res 2002; 62: 6395-6399.
  64. Lee Y., Miller H.L., Jensen P. et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003; 63: 5428-5437.
  65. Lescop S., Lellouch-Tubiana A., Vassal G., Basnard-Guerin C. Molecular genetic studies of chromosome 11 and chromosome 22q DNA sequences in pediatric medulloblastomas. J Neurol Oncol 1999; 44: 119-127.
  66. Li X-N., Shu Q., Su J.M. et al. Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol 2007; 33: 67-76.
  67. Lindsey J.C., Anderton J.A., Lusher M.E., Clifford S.C. Epigenetic events in medulloblastoma development. Neurosurg Focus 2005; 19: 5: 1-13.
  68. Lindsey J.C., Lusher M.E., Anderton J.A. et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 2004; 25: 5: 661-668.
  69. Lo K.C., Ma C., Bundy B.N. et al. Gain of 1q is a potential univariate negative prognostic marker for to survival in medulloblastoma. Clin Cancer Res 2007; 3: 23: 7022-7028.
  70. Lo K.C., Rossi M.R., Burkhardt T. et al. Overlay analysis of the oligonucleotide array gene expression profiles and copy number abnormalities as determined by array comparative genomic hybridization in medulloblastomas. Genes Chromosom Cancer 2007; 46: 53-66.
  71. Lo K.C., Rossi M.R., Eberhart C.G., Cowell J.K. Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization. Brain Pathol 2007; 17: 3: 282-296.
  72. McCabe M.G., Ichimura K., Liu L. et al. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 2006; 65: 6: 549-561.
  73. Mendrzyk F., Korshunov A., Toedt G. Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes Chromosom Cancer 2006; 45: 401-410.
  74. Mendrzyk F., Radlwimmer B., Joos S. et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005; 23: 8853-8862.
  75. Monje M., Beachy P.A., Fisher P.G. Hedgehog, Flies, Wnts and MYCs: the time has come for many things in medulloblastoma. J Clin Oncol 2011; 29: 11: 1395-1398.
  76. Muhlisch J., Bajanowski T., Rickert C.H. et al. Frequent but borderline methylation of p16INK4a and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurol Oncol 2007; 83: 1: 17-29, DOI: 10.1007/s11060-006-9309-8.
  77. Nam D.-H., Wang K.-C., Kim Y.-M. et al. The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of c-erB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. J Korean Med Sci 2000; 15: 452-456.
  78. Neben K., Korshunov A., Benner A. et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004; 64: 3103-3111.
  79. Nicholson J., Wickramasinghe C., Ross F. et al. Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridization and fluorescence in situ hybridization. J Clin Pathol Mol Pathol 2000; 53: 313-319.
  80. Northcott P.A., Hielscher T., Dubuc A. et al. Pediatric and adult sonic hedgehod medulloblastomas are clinically and moleculary distinct. Acta Neuropathol 2011; DOI: 10.1007/s00401-011-0846-7.
  81. Northcott P.A., Korshunov A., Witt H. et al. Medulloblastoma comprises four distinct molecular varianrs. J Clin Oncol 2010; 28 DOI:10.1200/JCO.2009.27.4324.
  82. Onguru O., Karslioglu Y., Ozcan A., Celik E. Anti-apoptotic and growth-promoting markers in adult medulloblastomas. Clin Neuropathol 2010; 29: 6: 384-389.
  83. Pan E., Pellarin M., Holmes E. et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 2005; 11: 13: 4733-4740.
  84. Park P.C., Taylor M.D., Mainprize T.G. et al. Transcriptional profiling of medulloblastoma in children. J Neurosurg 2003; 99: 534-541.
  85. Peringa J., Fung K-M., Muragaki Y., Trojanowski J.O. The cellular and molecular biology of medulloblastoma. Curr Opin Neurol 1995; 8: 437-440.
  86. Pfister S., Hartmann C., Korshunov A. Histology and molecular pathology of pediatric brain tumors. J Child Neurol 2009; 24: 11: 1375-1386.
  87. Pfister S.M., Korshunov A., Kool M. et al. Molecular diagnosis of CNS embryonal tumors. Acta Neuropathol 2010; 120: 5: 553-566.
  88. Pfister S., Remke M., Benner A. et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q, 17q, and the MYC/MYCN loci. J Clin Oncol 2009; 27: 1627-1636.
  89. Pfister S., Remke M., Toedt G. et al. Supratentorial primitive neuroectodermal tumors of the Central Nervous System frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes Chromosom Cancer 2007; 46: 839-851.
  90. Pfister S., Schlaeger C., Mendrzyk F. et al. Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucl Acids Res 2007; 35: 7: e51. DOI: 10.1093/nar/gkm094 .
  91. Piccirillo S.G.M., Binda E., Fiocco R. et al. Brain cancer stem cells. J Mol Med 2009; 87: 1087-1095.
  92. Pizer B.L., Clifford S.C. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 2009; 23: 4: 364-375.
  93. Polkinghorn W., Tarbell N. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 2007; 4: 295-304.
  94. Pomeroy S.L., Cho Y.-J. Molecular fingerprints of medulloblastoma and their application to clinical practice. Future Oncol 2011; 7: 3: 327-329.
  95. Pui C.-H., Gajjar A., Kane J.R. et al. Challenging issues in pediatric oncology. Nature Rev Clin Oncol 2011; DOI:10.1038/nrclinonc.2011.95.
  96. Raso A., Negrit F., Gregoriot A. et al. Successful isolation and long-term establishment of a cell line with stem-like features from an anaplastic medulloblastoma. Neuropathol Appl Neurobiol 2008; 34: 3: 306-315.
  97. Remke M., Hielscher T., Northcott P.A. et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011; 29: 2717-2723.
  98. Rickert C.H., Paulus W. Comparative genomic hybridization in Central and Peripheral Nervous System tumors of childhood and adolescence. J Neuropathol Exp Neurol 2004; 63: 5: 399-417.
  99. Rieber J., Remke M., Hartmann C. et al. Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. Genes Chromosom Cancer 2009; 48: 7: 558-568.
  100. Rossi M.R., Conroy J., McQuaid D. et al. Array CGH analysis of pediatric medulloblastomas. Genes Chromosom Cancer 2006; 45: 290-303.
  101. Roussel M.F. New concepts in organ site research on medulloblastoma: genetics and genomics. Future Oncol 2010; 6: 8: 1229-1231.
  102. Rubin J.B., Rowitch D.H. Medulloblastoma: a problem of developmental biology. Cancer Cell 2002; 2: 1: 7-8.
  103. Rudin C.M., Hann C.L., Laterra J. et al. Treatment of medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. New Engl J Med 2009; 361: 1173-1178.
  104. Russo C., Pellarin M., Tingby O. et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 1999; 86: 331-339.
  105. Scott D.K., Straughton D., Cole M. et al. Identification and analysis of tumor suppressor loci at chromosome 10q23.3-10q25.3 in medulloblastoma. Cell Cycle 2006; 5: 20: 2381-2389.
  106. Shimato S., Natsume A., Takeuchi H. et al. Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma. Gene Therapy 2007; 14: 15: 1132-1142.
  107. Siu I-M., Lal A., Blankenship J.R. et al. C-MYC promoter activation in medulloblastoma. Cancer Res 2003; 63: 4773-4776.
  108. Smaele E.De., Marcotullio L.Di., Ferretti E. et al. Chromosome 17p deletion in human medulloblastoma. A missing checkpoint in the Hedgehog pathway. Cell Cycle 2004; 3: 10: 111-114.
  109. Stearns D., Chaudhry A., Abel T.W. et al. C-MYC overexpression causes anaplasia in medulloblastoma. Cancer Res 2006; 66: 2: 673-681.
  110. Swartling F.J., Grimmer M.R., Hackett C.S. et al. Pleiotropic role for MYCN in medulloblastoma. Genes Development 2010; 24: 1059-1072.
  111. Taylor M.D., Liu L., Raffel C. et al. Mutation in SUFU predispose to medulloblastoma. Nature Genet 2002; 31: 3: 306-310.
  112. Taylor M.D., Mainprize T.G., Rutka J.T. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 2000; 47: 4: 888-901.
  113. Thompson M.C., Fuller C., Hogg T.L. et al. Genomic identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24: 1924-1931.
  114. Toftgard R. Hedgehod signaling in cancer. CMLS Cell Mol Life Sci 2000; 57: 1720-1731.
  115. Tong C.Y.K., Hui A.B.Y., Yin X-L. et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg (Pediatrics 2) 2004; 100: 187-193.
  116. Tong W-M., Ohgaki H., Huang H. et al. Null mutation of DNA strand break-binding molecule poly (ADP-ribose) polymerase causes medulloblastomas in p53 -/-mice. Am J Pathol 2003; 162: 1: 343-352.
  117. Traenka C., Remke M., Korshunov A. et al. Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res 2010; 70: 20: 8003-8014.
  118. Uesaka T., Shono T., Kuga D. et al. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensivity. J Neurooncol 2007; 84: 2: 119-129.
  119. Uziel T., Zindy F., Sherr C.J., Roussel M.F. The CDK ingibitor p18Ink4c is a tumor suppessor in medulloblastoma. Cell Cycle 2006; 5: 4: 363-365.
  120. Vagner-Capodano A.M., Zattara-Cannoni H., Gambarelli D. et al. Detection of i(17q) chromosome by fluorescent in situ hybridization (FISH) with interphase nuclei in medulloblastoma. Cancer Genet Cytogenet 1994; 78: 1-6.
  121. Waha A., Waha A., Koch A. et al. Epigenetic silencing of the HIC-1 gene in human medulloblastomas. J Neuropathol Exp Neurol 2003; 62:11: 1192-1201.
  122. Weiner H.L., Bakst R., Hurlbert M.S. et al. Induction of medulloblastomas in mice by Sonic Hedgehog, independent of Gli1,2. Cancer Res 2002; 62: 6385-6389.
  123. Willert J., Epping M., Pollack J.R. et al. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Developm Biol 2002; 2: 2-8.
  124. Wu X., Northcott P.A., Croul S., Taylor M.D. Mouse models of medulloblastoma. Chinese J Cancer 2011; 30: 7: 442-448.
  125. Yasue M., Tomita T., Engelhard H. et al. Prognostic importance of DNA ploidy in medulloblastoma of childhood. J Neurosurg 1989; 70: 385-391.
  126. Yin X.-L., Pang J.C.-S., Ng H.-K. Identification of a region of homozygous deletion on 8p22-23.1 in medulloblastoma. Oncogene 2002; 21: 1461-1468.
  127. Zurawel R.H., Allen C., Chiappa S. et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosom Cancer 2000; 27: 44-51.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.